Bleomycin-induced flagellate erythema: A case report and review of the literature

August 2014
Oncology Letters;2014, Vol. 8 Issue 2, p933
Academic Journal
Case Study
Bleomycin has been used most commonly in the treatment of Hodgkin's lymphoma, certain germ cell tumors (GCT) and for the sclerosis of recurrent pleural effusions. Bleomycin toxicity predominantly affects the skin and lungs. Skin toxicity includes Raynaud's phenomenon, hyperkeratosis, nail-bed changes and palmoplantar desquamation. Flagellate erythema is an unusual rash occurring specifically during bleomycin use. In the present study, we report a case of bleomycin-induced flagellate erythema in a patient with GCT. A 42-year-old male was diagnosed with stage IIIB testicular cancer and treated with bleomycin, etoposide and cisplatin chemotherapy. After 10 days from the initiation of treatment, the patient subsequently developed a generalized pruritus and erythematous linear rash that was most prominent on the trunk, and upper and lower extremities. The patient was commenced on a short course of low-dose oral prednisolone, 20 mg daily, and antihistamine. Consequently, bleomycin was withheld from the patient's treatment regimen. The present study describes the case, along with a review of the associated literature.


Related Articles

  • Indwelling Pleural Catheters. Bhatnagar, Rahul; Maskell, Nick A. // Respiration;Jun2014, Vol. 88 Issue 1, p74 

    Indwelling pleural catheters (IPC) are now established as one of the major tools for the management of recurrent pleural effusions. Their traditional role, which saw them only as second line treatment for malignant effusions, has now expanded. Recent evidence has not only suggested that they may...

  • Four-cycle ABVD more toxic for older patients with Hodgkin's lymphoma.  // Hem/Onc Today;5/25/2013, Vol. 14 Issue 10, p31 

    The article discusses the findings of a study which revealed a significant dose reduction, delay in treatment, toxicity and treatment-associated mortality among patients aged at least 60 years with early-stage Hodgkins lymphoma who took four cycles of treatment with doxorubicin, bleomycin,...

  • Bleomycin.  // Reactions Weekly;11/2/2013, Issue 1476, p9 

    The article presents a case study of a 74-year-old man who suffered from interstitial pneumonitis after being treated with bleomycin for Hodgkin's lymphoma.

  • Mistletoe preparation (Viscum Fraxini-2) as palliative treatment for malignant pleural effusion: a feasibility study with comparison to bleomycin. Gaafar, Rabab; Rahman, Abdel Rahman M Abdel; Aboulkasem, Fatma; El Bastawisy, Ahmed // Ecancermedicalscience;2014, Vol. 8 Issue 413-446, p1 

    Background: Malignant pleural effusion is a common problem in patients with solid tumours. It has a significant impact on quality of life, and, hence, there is a substantial need to investigate new agents to treat it. Patients and methods: This is a prospective randomised controlled study,...

  • Review: Thoracoscopic pleurodesis with talc may be the optimal technique in patients with malignant pleural effusion. Mathur, Praveen N. // ACP Journal Club;Sep/Oct2004, Vol. 141 Issue 2, p43 

    This article focuses on treatment of patients with malignant pleural effusion. Randomized Controlled Trials (RCTs) in any language of patients > 16 years of age having pleurodesis for pleural effusion in the context of metastatic cancer or a malignant process leading to pleural effusion that...

  • Successful management of a bilateral diaphragmatic lymphangioma. Yung-Ching Ming; Kin-Sun Wong; Chao-Jan Wang; Jin-Yao Lai // Pediatric Surgery International;Jun2007, Vol. 23 Issue 6, p591 

    A 5-year-old boy developed two episodes of massive chylothorax due to a huge bilateral diaphragmatic lymphangioma. Two episodes of chylothorax were well controlled only after parenternal octreotide. The lymphangioma showed more than 90% shrinkage after intralesional sclerotherapy with bleomycin.

  • ESHAP as salvage therapy for relapsed or refractory Hodgkin's lymphoma. Labrador, Jorge; Cabrero-Calvo, Mónica; Pérez-López, Estefanía; Mateos, María; Vázquez, Lourdes; Caballero, María; García-Sanz, Ramón // Annals of Hematology;Oct2014, Vol. 93 Issue 10, p1745 

    The management of relapsed or refractory Hodgkin's lymphoma (RR-HL) remains a challenge for hematologists and oncologists. Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care for RR-HL. However, one of the most controversial aspects is which the...

  • Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkins lymphoma: CALGB 59804. NL Bartlett; D Niedzwiecki; JL Johnson; JW Friedberg; KB Johnson; K van Besien; AD Zelenetz; BD Cheson; GP Canellos; For the Cancer Leukemia Group B // Annals of Oncology;Jun2007, Vol. 18 Issue 6, p1071 

    Background: Because of high single-agent activity and modest toxicity, we hypothesized the combination of gemcitabine (G), vinorelbine (V), and pegylated liposomal doxorubicin (D) would be an effective salvage therapy for Hodgkins lymphoma (HL). Patients and methods: A total of 91 patients...

  • Research & Markets: Brentuximab Vedotin - First Treatment Option for Relapsed Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (Subset of Non-Hodgkin Lymphoma).  // Biomedical Market Newsletter;8/23/2011, Vol. 21, p77 

    The article discusses the need for drugs with enhanced toxicity and efficacy in treating Hodgkin and non-Hodgkin lymphoma. It says that the relapse rate for Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) patients are 30% and 50%. It mentions the report "Brentuximab Vedotin: First...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics